AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00695188
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral administration Escalating dose (15, 20, 25 mg)
Trial: NCT00695188
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25 mg oral administration
Trial: NCT03693807
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Please see Detailed Description.
Trial: NCT03693807
Drug: Anti-EGFR (Panitumumab or Cetuximab)
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Please see Detailed Description.
Trial: NCT00622700
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet Oral administration
Trial: NCT01602185
Drug: Placebo (lactose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
Trial: NCT01469585
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg orally at the start of cycle 3 (study day 57) for 28 days.
Trial: NCT00942266
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00942266
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04029090
Drug: MCI-186
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 60 mg MCI-186 over 60 min will be intravenously administered.
Trial: NCT04029090
Drug: MCI-186
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 300 mg MCI-186 over 60 min will be intravenously administered.
Trial: NCT04029090
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 0.9% w/v saline over 60 min will be intravenously administered.
Trial: NCT03173625
Drug: AC-076 for s.c. administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilized AC-076A to be reconstituted with 1 mL of water for injection
Trial: NCT03173625
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile 0.9% w/v sodium chloride solution
Trial: NCT01199315
Drug: AZD1446
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule, Moderate Release
Trial: NCT01199315
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule
Trial: NCT03788863
Drug: Diflucortolone valerate (BAY866146)
RxNorm normalized name: diflucortolone valerate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow clinical administration
Trial: NCT00532714
Drug: Irinotecan plus capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan 80 mg/m2 intravenously for 90 minutes once a week for 2 weeks (Days 1 and 8) followed by 1-week rest period.~Capecitabine is administered orally at a dose of 1,000 mg/m2 twice daily (total daily dose 2,000 mg/m2) as an intermittent regimen in 3-week cycles (2 weeks of treatment followed by a 1-week rest period).
Trial: NCT01962870
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00210379
Drug: intrathecal methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00227617
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200mg/m2 IV q2 wk on day 1 over a 2-hour period.
Trial: NCT04274894
Drug: AndroGel 1.62%
RxNorm normalized name: Androgel 1.62% Transdermal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AndroGel 1.62% was packaged in pump bottles with quantities sufficient to accommodate study design and could have been dose adjusted between a minimum of 20.25 mg of T (1 pump actuation) and a maximum of 81.0 mg of testosterone (4 pump actuations). For the first study drug administration at the Day 1 Visit, and also at Week 2, Week 4, Week 16 ambulatory blood pressure monitoring (ABPM,) and End of Treatment Visits, participants applied the study drug while on site so that the site staff could observe the proper administration of study drug. If participants forgot to apply their AndroGel 1.62% dose at their regularly scheduled dosing time, they were to take the next dose at the next dosing time.
Trial: NCT02259738
Drug: Shuxuening injection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00329329
Drug: satraplatin and capecitabine
RxNorm normalized name: satraplatin
DrugBank: Satraplatin (DB04996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: satraplatin and capecitabine dose escalated per the dosing scheme
Trial: NCT04475432
Drug: TP-03, 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day
Trial: NCT01353781
Drug: AZD5363
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given AZD5363 capsules administered orally as a single dose, and then multiple twice-daily dosing following 3 to 7 days washout.
Trial: NCT00737685
Drug: cyclophosphamide, fludarabine , thymoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclophosphamide (50 mg/kg once daily i.v. on days -9, -8, -7 \& -6) fludarabine (30 mg/m2 once daily i.v. on days -5, -4, -3 \& -2) thymoglobulin (2.5 mg/kg once daily i.v. on days -3, -2 \& -1)
Trial: NCT00579280
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02675322
Drug: Danlou Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danlou tablets were approved by China Food and Drug Administration for the treatment of ischemic heart disease in 2005 (Z20050244).
Trial: NCT01524497
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference drug: trazodone hydrochloride prolonged-release tablet placebo (corresponding dummy drug of 75mg, 150mg active drug)
Trial: NCT02852824
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01012063
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of normal saline was given intravenously over one hour and 0.5ml was injected subcutaneously.
Trial: NCT03347396
Drug: BIVV009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sutimlimab was administered as intravenous (IV) infusion.
Trial: NCT01706666
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT03395600
Drug: B125S5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.125% as the test dose. After 3 min, 10 ml of 0.125% bupivacaine epidural was injected
Trial: NCT02595346
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: endothelial function is assessed by measuring the flow mediated dilatation of humeral artery in response to ischemia. the dilatation is evaluated by echotracking.~glycocalyx thickness is measured by the study of sublingual microcirculation with SDF imaging.~oxydative, inflammatory and coagulation parameters is assessed on plasma samples.
Trial: NCT00405158
Drug: Anti-pyretic medication, paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01827982
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be given as a single oral dose.
Trial: NCT03951259
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo pills are made identical to the investigating SM934 in appearance.
Trial: NCT03287232
Drug: Prasterone 6.5 mg (0.50%) Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily administration of a 6.5 mg (0.50%) prasterone vaginal insert.
Trial: NCT00031486
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical to active drug in appearance) 500 mg tablets, 4 tablets 3 times daily for 90 days.
Trial: NCT02600494
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03056729
Drug: BIIB076
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as single intravenous (IV) infusion
Trial: NCT03056729
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as single IV infusion
Trial: NCT03310580
Drug: AR-13324 Ophthalmic Solution 0.02%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered to each eye, once daily (QD) in the evening (PM) for 28 days
Trial: NCT03310580
Drug: AR-13324 Ophthalmic Solution 0.04%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered to each eye, once daily (QD) in the evening (PM) for 28 days
Trial: NCT03310580
Drug: AR-13324 Ophthalmic Solution Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered to each eye, once daily (QD) in the evening (PM) for 28 days
Trial: NCT03477266
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dummy identical tablets to mouthly dissolving mosapride tablets
Trial: NCT01172002
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine,50-100 mg/d, ORAL ,each day . Number of Cycles: until progression or unacceptable toxicity develops.~Predonine, 10 mg/d, ORAL, each day. If extra renal flare occurs, the dose of predonine may be increased to 1mg/kg/day for not more than 2 weeks.
Trial: NCT00733980
Drug: GSK561679
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK561679
Trial: NCT00977665
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet for 48 weeks
Trial: NCT00014547
Drug: BBR 3464
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00816855
Drug: docetaxel, cisplatin, fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neoadjuvant chemotherapy:docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly
Trial: NCT00554138
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dd for 7-10 days
Trial: NCT00554138
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 dd 20 mg for 7-10 days
Trial: NCT03797521
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo oral capsules
Trial: NCT01039610
Drug: GSK945237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose detailed in Arm description
Trial: NCT01039610
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablet
Trial: NCT00664599
Drug: Cytotoxic Combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse cyclophosphamide 1000 mg in perfusion, once monthly monthly. Azathioprine 3 mg/kg/body weight daily + prednisolone 0.5 mg/kg/daily.
Trial: NCT00799409
Drug: Placebo/ CONCERTA (methylphenidate HCl)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily on Lab School Day #1 and Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #2
Trial: NCT00799409
Drug: CONCERTA (methylphenidate HCl) / Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #1 and Placebo once daily on Lab School Day #2
Trial: NCT00562640
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients enrolled in dose levels II and III also undergo pre-infusion lymphodepletive conditioning comprising cyclophosphamide IV on day -2
Trial: NCT02175355
Drug: High dose of Micardis®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02175355
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04232683
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill given preoperatively
Trial: NCT03263611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single intradiscal injection
Trial: NCT03263611
Drug: AMG0103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single intradiscal injection
Trial: NCT01441284
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01823224
Drug: IV tylenol 1000mg and 2 oral capsule sugar pills
RxNorm normalized name: Tylenol Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV acetaminophen 1000mg and 2 oral capsule sugar pills were given to participants that were randomized to receive the IV acetaminophen. The same collection of pain scores and morphine equivalents was completed the same as the other group.
Trial: NCT02658864
Drug: lafutidine
RxNorm normalized name: lafutidine
DrugBank: Lafutidine (DB12770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of different doses, sex and medication conditions
Trial: NCT04512066
Drug: RO6889450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral RO6889450 QD.
Trial: NCT04512066
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral placebo QD.
Trial: NCT02792465
Drug: CFI-402257
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00243880
Drug: lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: investigators will treat the patients within 24 hours of symptom onset with short term high-dose lovastatin at escalating dosage. The escalating dosage levels will be 1, 3, 6, 8, and 10 mg/kg per day for 3 days.
Trial: NCT03260868
Drug: Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection.
Trial: NCT02771743
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02771743
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01573403
Drug: DLBS2411
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 caplet of DLBS2411 @250 mg and 1 placebo caplet, once daily
Trial: NCT01573403
Drug: Placebo DLBS2411
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo caplets of DLBS2411, once daily
Trial: NCT02931526
Drug: Tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients who have the definitive diagnosis to treat with tigecycline for bacterial infection will be started on tigecycline with a loading dose 200mg IV followed by 100mg IV every 12h.
Trial: NCT01877785
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to MHAA4549A
Trial: NCT00415519
Drug: MCI-186
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
Trial: NCT00415519
Drug: Placebo of MCI-186
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two ampoules of Placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
Trial: NCT00886106
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil (Ultiva®; Glaxo-Smith-Kline; Vienna, Austria) will be applied intravenously during 60 minutes through a dedicated infusion pump (TCI Alaris PK Syringe Pump, Cardinal Health, Baesweiler, Germany), with a Target Controlled Infusion (following the integrated software algorithm by Minto), reaching the initial 18ng/ml plasma concentration in 180 seconds. This corresponds to circa 0.7 µg kg-1 min-1
Trial: NCT03443895
Drug: AEF0117 oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6, 2 and 6mg of AEF0117
Trial: NCT03443895
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsule
Trial: NCT01473303
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01473303
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02141217
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin 150 mg qid for at least 5 days or maximum 7 days depending upon the treatment response.
Trial: NCT04202978
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine:850mg/m2 P.O ,bid ,d1-d14
Trial: NCT03235726
Drug: CCI15106
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule (single dose or repeat dose) of 30 mg of CCI15106 will be administered to healthy subjects and subjects with COPD via inhalation route using Monodose RS01 device. The morning dose will be taken in fasting state and for repeat dose; the evening dose will be taken at least 2 hours after food.
Trial: NCT03235726
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule of placebo will be administered to healthy subjects and subjects with COPD via inhalation route using Monodose RS01 device. The morning dose will be taken in fasting state and for repeat dose; the evening dose will be taken at least 2 hours after food.
Trial: NCT02361619
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: probe
Trial: NCT02361619
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: probe
Trial: NCT02361619
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: perpetrator
Trial: NCT01022151
Drug: Placebo [group P]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: receive intravenous injection of 0.2 mL/kg of saline 0.9%L \[group P\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
Trial: NCT00481572
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: titrated norepinephrine over a period of 48 hrs
Trial: NCT04697277
Drug: Antibiotic prophylaxis timing (before skin incision and after cord clamping) for caesarean section
RxNorm normalized name: gonorrheal urethral secretion human
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02317926
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02317926
Drug: Levothyroxine Plus Liothyronine
RxNorm normalized name: LEVOTHYROXINE/LIOTHYRONINE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02317926
Drug: Desiccated Thyroid Extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01673399
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00759798
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250 mg/m2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond.
Trial: NCT03258398
Drug: eFT508
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eFT508 will be taken orally (PO) twice a day (bid).
Trial: NCT01779050
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02162121
Drug: Ketorolac 30mg
RxNorm normalized name: ketorolac 30 MG
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00109772
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two placebo capsules taken one time per day
Trial: NCT01989754
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo capsule taken orally (by mouth) once daily for 156 weeks
Trial: NCT02516150
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion of ethanol to stabilize BAC (blood alcohol content) at 0.1%
Trial: NCT00618995
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablets for each of the interventions once daily for 7 days
Trial: NCT01779050
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00385606
Drug: rofecoxib
RxNorm normalized name: Rofecoxib
DrugBank: Rofecoxib (DB00533)
FDA approved: yes
EMA approved: no
PMDA approved: no